Clinical trial
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
NCT00116376 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00116376 |
|---|---|
| Title | Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) |
| Official title | A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | AEE788 |
| Enrollment | 64 |
| Start date | Jan 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Jun 29, 2005 |
| Last update posted | Nov 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: